SCHEMBL4124937

SCHEMBL4124937

CCC1(CC)CCCCC(C(=O)OC)C1=O

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DNTT P04053 1/20 0.35
▸ CYP1A2 P05177 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ TLR4 O00206 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ FKBP1A P62942 2/20 0.32
▸ CCR2 P41597 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ OPRK1 P41145 2/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HSD11B1 P28845 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ ALOX12 P18054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29329319 0.89 CYP1A2 (0.36) DNTTCYP1A2HIF1AKDM4EALDH1A1
SCHEMBL5254413 0.83 TSHR (0.34) DNTTCYP1A2HIF1ATLR4KDM4E
SCHEMBL4123910 0.79 FKBP1A (0.40) CYP1A2KDM4EHSD17B10ALDH1A1FKBP1A
SCHEMBL3813382 0.79 KDM4E (0.37) CYP1A2HIF1AKDM4EHSD17B10ALDH1A1
SCHEMBL4128790 0.79 CYP1A2 (0.36) DNTTCYP1A2HIF1AKDM4EHSD17B10
SCHEMBL22309984 0.78 CYP1A2 (0.35) DNTTCYP1A2HIF1AKDM4EHSD17B10
SCHEMBL3339309 0.77 CYP1A2 (0.37) CYP1A2HIF1AKDM4EHSD17B10ALDH1A1
SCHEMBL3399318 0.76 CYP1A2 (0.36) CYP1A2HIF1AKDM4EHSD17B10ALDH1A1
SCHEMBL3236730 0.73 CYP1A2 (0.37) CYP1A2HIF1AKDM4EHSD17B10ALDH1A1
SCHEMBL4121606 0.72 CYP1A2 (0.36) CYP1A2HIF1AKDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP DNTT 360/4885CYP1A2 1655/4885HIF1A 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback